HOME > TOP STORIES

TOP STORIES

ORGANIZATION Study Group Presents Proposal for Future Vision for Kampo Medicines

March 21, 2017
BUSINESS Court Finds Data Manipulation, but Not False Advertising: Diovan Case

March 17, 2017
BUSINESS Novartis, Ex-Employee Found Not Guilty in Diovan Case

March 16, 2017
REGULATORY Chuikyo Begins Debate on Gap-Year Price Revisions; Industry Frets Advance Announcement of Discrepancy Threshold

March 16, 2017
BUSINESS Takeda Biotech JV to Focus on 8 Projects for Now, Eyes IPO: CEO Okumura

March 15, 2017
REGULATORY Celgene Faces Biz Improvement Order over Delays in Side Effect Reporting

March 15, 2017
BUSINESS INCJ, Takeda, Medipal to Form Biotech Venture

March 14, 2017
BUSINESS 1st Line Use, Administration Interval Will Be Key Differentiator for Keytruda: MSD Japan Chief

March 14, 2017
REGULATORY Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni

March 14, 2017
REGULATORY Reference Pricing on Agenda for CEFP Social Security Working Group

March 10, 2017
BUSINESS Pfizer’s FY2016 Japan Sales Slide 7.4% on Price Cuts, Generic Erosions

March 9, 2017
REGULATORY MHLW to Set Up Panel on Drug Distribution after Fake Harvoni Flub, Eyes GDP Ordinance

March 8, 2017
REGULATORY Tap Real-World Data for Optimal Use of High-Priced Meds: MHLW Bureau Chief

March 7, 2017
COMMENTARY Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight

March 7, 2017
INTERVIEW Chugai to Execute Area-Based Strategy Centering on General Reps: Marketing Chief

March 6, 2017
BUSINESS Bioverativ Japan Now Up and Running, Set to Keep Double-Digit Growth: President

March 3, 2017
REGULATORY 7 Products Including iPS Cell-Derived Product Receive Sakigake Review Status in the Second Round of Designations

March 2, 2017
ORGANIZATION EFPIA Japan to Compile Policy Proposal on Pricing Reform by Early April: New Chair

March 1, 2017
INTERVIEW Daiichi Sankyo Espha Eyes 50 Billion Yen Sales in 2020 with AGs as Growth Engine

February 28, 2017
BUSINESS Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President

February 27, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

More Positions, More Candidates: A Snapshot of Movement in Japan’s Pharma Industry

By Philip Carrigan

Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…